bromocriptine

(redirected from Cycloset)
Also found in: Medical, Encyclopedia.
Related to Cycloset: bromocriptine

bro·mo·crip·tine

 (brō′mō-krĭp′tēn)
n.
An ergot alkaloid, C32H40BrN5O5, that is a dopamine antagonist and is used in its mesylate form to treat Parkinson's disease, acromegaly, and excessive prolactin secretion, and to reduce the size of certain pituitary tumors.

[bromo- + (ergo)cryptine, an ergot alkaloid (from German Ergokryptin : Ergo(t), ergot + Greek kruptos, hidden; see cryptic + -in, -in).]

bromocriptine

(ˌbrəʊməʊˈkrɪptiːn)
n
a dopamine agonist drug which blocks the release of prolactin from the pituitary gland, used in the treatment of Parkinson's disease
Translations

bromocriptine

n bromocriptina
References in periodicals archive ?
A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either cycloset or placebo.
name of Cycloset tablet, from S2 Therapeutics and VeroScience, at five
Now, the company's product portfolio offers 22 marketed products, including XIFAXAN, UCERIS, GLUMETZA, APRISO, ZEGERID, MOVIPREP, RELISTOR, SOLESTA, FULYZAQ, CYCLOSET and DEFLUX.
License fees and royalties include royalties on GLUMETZA net sales, the gross margin split on CYCLOSET net sales, royalties on ZEGERID net sales and amortization of upfront payments.
rights to Cycloset and plans to start selling the drug in November.
Cycloset is the first approved treatment for type 2 diabetes that seeks to improve dopamine activity in the brain--which studies have linked to better insulin control.
But unlike its older parent, Cycloset is formulated to require a low, quick-acting dose taken just in the morning -- no other time of day.
7) In the Cycloset Safety Study, for instance, bromocriptine QR combined with standard diabetes therapy (diet plus oral hypoglycemic agents as needed) was compared with standard diabetes therapy plus placebo in more than 3,000 patients.
M2 PHARMA-November 15, 2010-Santarus launches Type 2 diabetes drug CYCLOSET in USA(C)2010 M2 COMMUNICATIONS
M2 EQUITYBITES-September 9, 2010-Santarus Inc licenses CYCLOSET for type 2 diabetes(C)2010 M2 COMMUNICATIONS http://www.
9 September 2010 - US-based biopharmaceutical company Santarus Inc (NASDAQ: SNTS), S2 Therapeutics Inc and VeroScience LLC today announced they have entered into a distribution and licence agreement granting Santarus exclusive rights to manufacture and commercialise CYCLOSET tablets in USA.
Cycloset, a quick-release oral formulation of bromocriptine mesylate, was recently approved by the Food and Drug Administration as a treatment for type 2 diabetes, according to the manufacturers, VeroScience and S2 Therapeutics Inc.